|
WO2020165352A1
|
|
Treatment of ciliopathies
|
|
WO2020165158A1
|
|
Mrna purification by tangential flow filtration
|
|
WO2020074642A1
|
|
Plasmid containing a sequence encoding an mrna with a segmented poly(a) tail
|
|
CA3109548A1
|
|
Lipid-based formulations containing salts for the delivery of rna
|
|
AU2019258679A1
|
|
Cryoprotective agents for particulate formulations
|
|
WO2019158583A1
|
|
Polyribonucleotide containing deuterated nucleotides
|
|
US2020308556A1
|
|
Ornithine transcarbamylase coding polyribonucleotides and formulations thereof
|
|
US2018163213A1
|
|
Cas9 mRNAs
|
|
AU2017242794A1
|
|
Novel minimal UTR sequences
|
|
WO2017046259A1
|
|
Improved transposon system for gene delivery
|
|
KR20180021856A
|
|
ATP-binding cassette family-coding polyribonucleotides and their preparations
|
|
CA2990881A1
|
|
Utrs increasing the translation efficiency of rna molecules
|
|
WO2016207300A1
|
|
Enhanced cell reprogramming by mrna
|
|
EP3542825A1
|
|
Induction of osteogenesis by delivering bmp encoding rna
|
|
US2017189552A1
|
|
RNA for use in the treatment of ligament or tendon lesions
|
|
AU2014384269A1
|
|
Compositions for gastrointestinal administration of RNA
|
|
EP3034539A1
|
|
Compositions for introducing nucleic acid into cells
|
|
US2017021036A1
|
|
Compositions for introducing rna into cells
|
|
BR112014030677A2
|
|
pulmonary distribution of mrna to non-pulmonary target cells
|
|
EP3800254A1
|
|
Pulmonary delivery of messenger rna
|
